Academic Profile : Faculty
Assoc Prof Torsten Wuestefeld
Associate Professor of Molecular Metabolism, Lee Kong Chian School of Medicine
Associate Professor, Lee Kong Chian School of Medicine
ACADEMIC QUALIFICATIONS:
• University of Hannover, PhD, Faculty of Chemistry, 2002, Molecular analysis of IL-6/gp130 dependent signal transduction pathways during liver regeneration (Research work was done in the Department of Gastroenterology, Hepatology & Endocrinology, Medical School Hannover, Hannover, Germany)
• University of Hannover, Master of Science, Faculty of Biology, 1998, Molecular biological characterization of the ´fasciata´-syndrom of the pea (Pisum Sativum)
POSITION & HONORARY APPOINTMENTS:
• 2023-present: Assoc/Prof. of Molecular Metabolism, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore
• 2015-present: Group Leader, Genome Institute of Singapore, Laboratory of In Vivo Genetics and Gene Therapy, Singapore
• 2019-present: Adjunct Prof. Nanyang Technological University, School of Biological Sciences
• 2020-present: Scientific Co-Founder and Scientific Advisor, LERNA Biopharma (formerly known as Cargene Therapeutics), Singapore
PATENTS:
Zender, L, Wüstefeld, T, WO2012136859: Medicament for liver regeneration and for treatment of liver failure.
Iakovleva, V., Wuestefeld, T. WO2022025827: Method of stimulating proliferation of a cell.
Hora, S., Kaur, A. Wuestefeld, T. SG patent application no.: 10202301535X: Enhancing liver regeneration and counteracting liver disease.
Potapova, A., Wuestefeld, T.: SG patent application no.: 10202302421T: GENE SIGNATURES FOR LIVER DISEASE AND USES THERE OF.
SIGNIFICANT AWARDS:
2021 Public Sector Transformation (PST) Awards – One Public Service Award, in recognition of contributions to Building Capacity & Capability for COVID-19 Testing
2021 Firefly Award-Borderless Award (Gold) in recognition of contributions to the Stronghold Diagnostic Lab (SDL) in Singapore
2020 Cargen Therapeutics co –founded by T. Wuestefeld got the Golden Ticket awarded by Novo Nordisk and LabCentral
2004-05 2 year scholarship of the DFG (DFG-Project WU 373/1-1)
1999-2001 Scholarship of the DFG, Graduiertenkolleg (GRK 139/3-00) “Molecular Pathophysiology of the cell growth”
1995-1996 Scholarship of the German Academic Exchange Program (DAAD) for studying at Northeastern University, Boston, USA
RESEARCH INTERESTS:
Liver Disease Modelling, NAFLD, Metabolic syndrome, Aging, Senescence, Liver Cancer, Gene Therapy, Nucleic Acid Therapeutics, In Vivo Functional Genetic Screens, Translational Research
• University of Hannover, PhD, Faculty of Chemistry, 2002, Molecular analysis of IL-6/gp130 dependent signal transduction pathways during liver regeneration (Research work was done in the Department of Gastroenterology, Hepatology & Endocrinology, Medical School Hannover, Hannover, Germany)
• University of Hannover, Master of Science, Faculty of Biology, 1998, Molecular biological characterization of the ´fasciata´-syndrom of the pea (Pisum Sativum)
POSITION & HONORARY APPOINTMENTS:
• 2023-present: Assoc/Prof. of Molecular Metabolism, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore
• 2015-present: Group Leader, Genome Institute of Singapore, Laboratory of In Vivo Genetics and Gene Therapy, Singapore
• 2019-present: Adjunct Prof. Nanyang Technological University, School of Biological Sciences
• 2020-present: Scientific Co-Founder and Scientific Advisor, LERNA Biopharma (formerly known as Cargene Therapeutics), Singapore
PATENTS:
Zender, L, Wüstefeld, T, WO2012136859: Medicament for liver regeneration and for treatment of liver failure.
Iakovleva, V., Wuestefeld, T. WO2022025827: Method of stimulating proliferation of a cell.
Hora, S., Kaur, A. Wuestefeld, T. SG patent application no.: 10202301535X: Enhancing liver regeneration and counteracting liver disease.
Potapova, A., Wuestefeld, T.: SG patent application no.: 10202302421T: GENE SIGNATURES FOR LIVER DISEASE AND USES THERE OF.
SIGNIFICANT AWARDS:
2021 Public Sector Transformation (PST) Awards – One Public Service Award, in recognition of contributions to Building Capacity & Capability for COVID-19 Testing
2021 Firefly Award-Borderless Award (Gold) in recognition of contributions to the Stronghold Diagnostic Lab (SDL) in Singapore
2020 Cargen Therapeutics co –founded by T. Wuestefeld got the Golden Ticket awarded by Novo Nordisk and LabCentral
2004-05 2 year scholarship of the DFG (DFG-Project WU 373/1-1)
1999-2001 Scholarship of the DFG, Graduiertenkolleg (GRK 139/3-00) “Molecular Pathophysiology of the cell growth”
1995-1996 Scholarship of the German Academic Exchange Program (DAAD) for studying at Northeastern University, Boston, USA
RESEARCH INTERESTS:
Liver Disease Modelling, NAFLD, Metabolic syndrome, Aging, Senescence, Liver Cancer, Gene Therapy, Nucleic Acid Therapeutics, In Vivo Functional Genetic Screens, Translational Research
Dr. Torsten Wuestefeld has more than 3 decades of experience in unravelling liver biology. His group focuses on dissecting liver regeneration and liver disease to better understand the underlying process for the identification of new therapeutic as well as diagnostic approaches. Using relevant mouse models, in vivo functional genomics and human patient data they identify new therapeutic targets to treat liver disease, translating into IP and biotech startups. As a result of their research they are bridging the gaps from bench to bedside, from therapeutics to biomarkers and from mouse to human.
Currently the group is especially focusing on the manifestation of the metabolic syndrome in the liver, fatty liver disease; the brain-liver-gut axis; NASH driven liver cancer; impact of senescent liver cells on liver pathobiology and ageing.
Currently the group is especially focusing on the manifestation of the metabolic syndrome in the liver, fatty liver disease; the brain-liver-gut axis; NASH driven liver cancer; impact of senescent liver cells on liver pathobiology and ageing.
- Dissection of metabolic disease impact on liver, heart and brain